Anbio Biotechnology (NNNN) Q4 2024 earnings summary

Executive summary

• Achieved $8.19M in revenue for 2024, up 21.9% from 2023, driven by expanded non-COVID product portfolio and broader client base across regions.

• Gross profit for 2024 was $5.89M (gross margin 71.9%), up from $3.36M in 2023, reflecting improved purchasing efficiency and higher-margin services.

• Net income for 2024 was $2.37M, slightly up from $2.25M in 2023, but down from $10.01M in 2022 due to the decline in COVID-19 test demand.

• Completed IPO in February 2025, raising $8M in gross proceeds.

Financial highlights

• Revenue: $8.19M (2024), $6.71M (2023), $23.54M (2022).

• Gross profit: $5.89M (2024), $3.36M (2023), $12.56M (2022).

• Gross margin: 71.9% (2024), 50.1% (2023), 53.4% (2022).

• SG&A expenses: $3.44M (2024), up 171.6% from 2023, mainly due to IPO-related costs.

• R&D expenses: $454K (2024), up 237% from 2023, reflecting increased investment in new assays and devices.

• Net income: $2.37M (2024), $2.25M (2023), $10.01M (2022).

• Cash and cash equivalents: $11.76M as of Dec 31, 2024.

Outlook and guidance

• Management expects continued growth from non-COVID IVD products and further global market expansion.

• Current cash and IPO proceeds are expected to fund operations and expansion for at least the next 12 months.

• No significant trends or uncertainties expected to materially affect future results, aside from ongoing regulatory and market risks.